The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
Srivastava, Stuti; Goswami, Lalit N.; Dikshit, Dinesh K., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2003, vol. 42, # 10, p. 2628 - 2631
作者:Srivastava, Stuti、Goswami, Lalit N.、Dikshit, Dinesh K.
DOI:——
日期:——
US8871759B2
申请人:——
公开号:US8871759B2
公开(公告)日:2014-10-28
US9090661B2
申请人:——
公开号:US9090661B2
公开(公告)日:2015-07-28
Highly selective tripeptide thrombin inhibitors
作者:Robert T. Shuman、Robert B. Rothenberger、Charles S. Campbell、Gerald F. Smith、Donetta S. Gifford-Moore、Paul D. Gesellchen
DOI:10.1021/jm00055a002
日期:1993.2
potent direct inhibition of thrombin. This distinction offers important insight for the design of more potent and selective serine proteaseinhibitors which may be useful pharmacological tools and hold promise for development of clinically useful agents. The structure-activityrelationships (SAR) on a series of anticoagulant peptides with high selectivity for the enzyme thrombin are discussed. The SAR